CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
Authors
Armentero M. T.
Blandini F.
+3 more
Blaugrund E.
Fancellu R.
Nappi G.
Publication date
1 January 2004
Publisher
'Elsevier BV'
Doi
Cite
Abstract
Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and were treated daily for 6 weeks with increasing doses of monoamine oxidase type B inhibitor rasagiline [R(+)-N-propargyl-1- aminoindane] or saline (controls). Both doses of rasagiline markedly increased the survival of dopaminergic neurons in the lesioned substantia nigra, compared to controls (+97% and +119%, respectively). Treatment with the lower dose of rasagiline also abolished the motor stereotypies associated with nigrostriatal lesion. Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD). © 2004 Elsevier Inc. All rights reserved
Similar works
Full text
Available Versions
Archivio Istituzionale della Ricerca - Università degli Studi di Pavia
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:iris.unipv.it:11571/142449...
Last time updated on 11/07/2022